Murphy P, Johnson D H
Division of Medical Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee.
Hematol Oncol Clin North Am. 1991 Dec;5(6):1233-43.
Staging of nonseminomatous testicular cancers, as with other tumors, renders important prognostic information and is necessary for making appropriate treatment recommendations. There is no universally accepted staging system for testis cancer, however. Despite the lack of uniformity, most of the staging systems in use today are capable of segregating patients into a "good-risk" or "poor-risk" category. The former group experiences cure less frequently and are appropriate candidates for investigational treatment. Tumor bulk is the most important prognostic factor in virtually all staging systems.
与其他肿瘤一样,非精原细胞瘤性睾丸癌的分期可提供重要的预后信息,并且对于做出恰当的治疗建议而言是必要的。然而,目前尚无一个被普遍接受的睾丸癌分期系统。尽管缺乏统一性,但如今使用的大多数分期系统都能够将患者分为“低风险”或“高风险”类别。前一组患者的治愈率较低,是进行试验性治疗的合适人选。在几乎所有分期系统中,肿瘤大小都是最重要的预后因素。